{"id":8347,"date":"2018-02-02T23:53:37","date_gmt":"2018-02-02T23:53:37","guid":{"rendered":"https:\/\/oxfordcorp.com\/key-changes-and-important-deadlines-for-mdr\/"},"modified":"2026-09-02T15:43:03","modified_gmt":"2026-09-02T15:43:03","slug":"key-changes-and-important-deadlines-for-mdr","status":"publish","type":"post","link":"https:\/\/www.oxfordcorp.com\/en\/insights\/blog\/key-changes-and-important-deadlines-for-mdr\/","title":{"rendered":"EU MDR Transition Deadlines: What Manufacturers Need to Know for 2026\u20132028\u00a0"},"content":{"rendered":"

Last updated: September 2, 2026<\/em><\/strong><\/p>\n

Quick answer:<\/span><\/b> EU MDR transition deadlines are staggered by device class. Custom-made Class III devices needed to be compliant by May 26, 2026. Class III and most implantable Class IIb devices have until December 31, 2027. Other Class IIb devices, Class IIa, Class I devices requiring Notified Body involvement, and certain up-classified Class I devices have until December 31, 2028. To qualify for the extended dates, manufacturers needed an MDR-compliant quality management system in place by May 26, 2024, and a signed Notified Body agreement by September 26, 2024. The old “sell-off” deadline has been removed, so qualifying legacy devices can stay on the market without a fixed stock-clearance date.<\/span>\u00a0<\/span><\/p>\n

_____________________________________________________________________________________________________<\/p>\n

The <\/span>European Union’s Medical Device Regulation (EU MDR 2017\/745)<\/span><\/a> became fully applicable in May 2021, replacing the older Medical Device Directive (MDD) framework. Since then, the timeline has shifted more than once, and the deadlines that matter most for the majority of manufacturers are still ahead of us in 2026, 2027, and 2028.<\/span>\u00a0<\/span><\/p>\n

If your organization sells devices into the EU market, here is where things actually stand today, and what you should prioritize next.<\/span>\u00a0<\/span><\/p>\n

Why the Original Timeline Changed<\/span>\u00a0<\/span><\/h2>\n

MDR was approved in 2017 and phased in through 2021 but Notified Body capacity could not keep pace with demand. Thousands of devices risked losing market access simply because certification bodies could not process applications fast enough, not because manufacturers were non-compliant in substance.<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span>To prevent shortages, <\/span>the European Commission adopted Regulation (EU) 2023\/607 in March 2023<\/span>.<\/span><\/a> This amendment extended the transition periods based on device risk classification and removed the fixed “sell-off” deadline that previously forced manufacturers to clear MDD-compliant stock by a set date. Qualifying legacy devices can now stay on the market without a hard stock-clearance cutoff, provided they continue to meet the extension conditions.<\/span>\u00a0<\/span><\/p>\n

Current Deadlines by Device Class<\/span><\/b>\u00a0<\/span><\/p>\n